Literature DB >> 6617867

Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin.

A Ichinose, T Tamaki, N Aoki.   

Abstract

The NH2-terminal 12-residue peptide of alpha 2-plasmin inhibitor, Asn-Gln-Glu-Gln-Val-Ser-Pro-Leu-Thr-Gly-Leu-Lys-NH2 . AcOH, was found to be a good substrate for plasma transglutaminase (activated blood coagulation factor XIII) and rapidly incorporated into fibrin by the enzyme. A high concentration of the peptide inhibited the enzyme-mediated cross-linking of alpha 2-plasmin inhibitor to fibrin probably by competing with the inhibitor for the same site of fibrin alpha-chain.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6617867     DOI： 10.1016/0014-5793(83)80645-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  14 in total

Review 1.  Molecular basis of thrombolytic therapy.

Authors:  H R Lijnen; D Collen
Journal:  J Nucl Cardiol       Date:  2000 Jul-Aug       Impact factor: 5.952

2.  Delivery of neurotrophin-3 from fibrin enhances neuronal fiber sprouting after spinal cord injury.

Authors:  Sara J Taylor; Ephron S Rosenzweig; John W McDonald; Shelly E Sakiyama-Elbert
Journal:  J Control Release       Date:  2006-06-22       Impact factor: 9.776

3.  Evaluating factor XIII specificity for glutamine-containing substrates using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay.

Authors:  Prakash G Doiphode; Marina V Malovichko; Kelly Njine Mouapi; Muriel C Maurer
Journal:  Anal Biochem       Date:  2014-04-19       Impact factor: 3.365

4.  Effect of controlled delivery of neurotrophin-3 from fibrin on spinal cord injury in a long term model.

Authors:  Sara J Taylor; Shelly E Sakiyama-Elbert
Journal:  J Control Release       Date:  2006-07-08       Impact factor: 9.776

5.  Hybrid photopatterned enzymatic reaction (HyPER) for in situ cell manipulation.

Authors:  Donald R Griffin; Jacob Borrajo; Allyson Soon; Giovanny F Acosta-Vélez; Victor Oshita; Nicole Darling; Julia Mack; Thomas Barker; M Luisa Iruela-Arispe; Tatiana Segura
Journal:  Chembiochem       Date:  2014-01-07       Impact factor: 3.164

Review 6.  Fibrinolysis and the control of blood coagulation.

Authors:  John C Chapin; Katherine A Hajjar
Journal:  Blood Rev       Date:  2014-09-16       Impact factor: 8.250

Review 7.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

8.  The effect of controlled growth factor delivery on embryonic stem cell differentiation inside fibrin scaffolds.

Authors:  Stephanie M Willerth; Allison Rader; Shelly E Sakiyama-Elbert
Journal:  Stem Cell Res       Date:  2008-06-10       Impact factor: 2.020

9.  Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.

Authors:  J Mimuro; S Kimura; N Aoki
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

10.  Affinity-based release of glial-derived neurotrophic factor from fibrin matrices enhances sciatic nerve regeneration.

Authors:  Matthew D Wood; Amy M Moore; Daniel A Hunter; Sami Tuffaha; Gregory H Borschel; Susan E Mackinnon; Shelly E Sakiyama-Elbert
Journal:  Acta Biomater       Date:  2008-12-06       Impact factor: 8.947
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.